J&J Commits Five-Year Investment in Italian Medicine Manufacturing Expansion

20 Jun, 2024

J&J Commits Five-Year Investment in Italian Medicine Manufacturing Expansion

Johnson & Johnson Innovative Medicine plans to invest €580 million in Italy over the next five years, enhancing its Latina site's production capacity. Currently, the Latina site exports 97 percent of the medicine it produces, making it a crucial part of J&J's global supply chain. The investment includes €125 million dedicated to expanding production capabilities at the Latina facility, which produces over four billion tablets annually across approximately 30 different products.

The site has been designated as an Industry 4.0 location by the World Economic Forum, highlighting its commitment to innovation and sustainability. General Manager Jorge Lopez emphasized the importance of building future capabilities by investing in advanced technology and workforce development. This investment is expected to increase production capacity by over 25 percent, making the site more agile and efficient.

The new technologies will streamline manufacturing processes, allowing for simultaneous rather than sequential operations, thereby reducing end-to-end manufacturing time and improving packaging management of small production batches. A significant challenge during this transition has been upskilling employees to ensure they can implement innovative solutions effectively. This strategic investment underscores J&J's dedication to maintaining resilience and reliability in supplying innovative medicines globally.